Boston Scientific Corporation (BSX)
Will Robust Cardiovascular Performance Fuel BSX's Q3 Earnings?
Boston Scientific's strong cardiovascular and MedSurg momentum, powered by innovations like WATCHMAN FLX Pro and AGENT DCB, could drive solid Q3 results.
4 Top AI-Powered Healthcare Stocks
Healthcare stocks quietly outperformed the market in the past 30 days as headlines centered on the government shutdown over the extension of Affordable Care Act tax credits for 2026. The AI in healthcare market is expected to reach $504B by 2032, driven by an aging population, medical data explosion, job shortages, and consumer demand for self-care technology. Healthcare companies are increasingly deploying AI in drug discovery, diagnostics, imagery, robot-assisted surgery, and hospital administration.
Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts
The latest trading day saw Boston Scientific (BSX) settling at $95.85, representing a -1.82% change from its previous close.
Boston Scientific Corporation (BSX) Analyst/Investor Day Transcript
Boston Scientific Corporation (NYSE:BSX ) Analyst/Investor Day September 30, 2025 8:30 AM EDT Company Participants Lauren Tengler - Director of Investor Relations Michael Mahoney - Chairman, President & CEO Arthur Butcher - Executive VP and Group President of MedSurg & Asia Pacific Jim Cassidy Meghan Scanlon Adam Smith Brian Dunkin Joseph Fitzgerald - Executive VP & Group President of Cardiology Peter Pattison - President of the Interventional Oncology Division Catherine Jennings Lance Bates Janarthanan Sathananthan - Chief Medical Officer of Interventional Cardiology Therapies Scott Olson Ken Stein - Senior VP & Global Chief Medical Officer Angelo De Rosa Brad Sutton Nicholas Spadea-Anello Jonathan Monson - Executive VP & CFO Conference Call Participants Joanne Wuensch - Citigroup Inc., Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division David Rescott - Robert W. Baird & Co. Incorporated, Research Division Jayson Bedford - Raymond James & Associates, Inc., Research Division Pito Chickering - Deutsche Bank AG, Research Division Travis Steed - BofA Securities, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Michael Polark - Wolfe Research, LLC Joshua Jennings - TD Cowen, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Michael Matson - Needham & Company, LLC, Research Division Marie Thibault - BTIG, LLC, Research Division Matthew Taylor - Jefferies LLC, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Richard Newitter - Truist Securities, Inc., Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Conversation Operator Please welcome Lauren Tengler.
3 Healthcare Stocks Using AI to Drive Growth
Artificial intelligence (AI) is transforming the world in much the same way as the adoption of the internet did 30 years ago. This is about more than just search; AI is changing the way many industries handle administrative tasks.
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
Here is how Boston Scientific (BSX) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.
4 Medical Devices Behemoths to Buy Amid Extensive AI Applications
AI-driven innovations in medical devices are fueling growth for BSX, JNJ, GEHC and TEM.
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
Here is how Boston Scientific (BSX) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
3 Reasons Growth Investors Will Love Boston Scientific (BSX)
Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Boston Scientific Corporation Is Expensive But Worth It
Boston Scientific is a 'forever stock' due to management foresight, robust R&D, and leadership in AI-driven medical devices. Despite a weak valuation grade, its strong financials, global expansion, and AI integration justify a long-term buy rating. Key risks include regulatory changes, insider selling, and potential revenue impacts from federal healthcare cutbacks; buy on dips is advised.
Investors Heavily Search Boston Scientific Corporation (BSX): Here is What You Need to Know
Zacks.com users have recently been watching Boston Scientific (BSX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
